Castrate Resistant

Advanced Prostate

Hormone Naive

Non-Metastatic

Metastatic

Non-Metastatic

1st Line
No prior AR
Targeting Agent

2nd Line
Post-AR targeting Agent

Chemotherapy Naive

Post Taxane-based
Chemotherapy

Supportive Care/Biomarker

Metastatic

No Trials Currently Available

IRB # 11268
Salvage radiation + enzalutamide/pla cebo for recurrent prostate cancer

IRB # 19633
SWOG 1802: SST +/- definitive tx for metastatic disease

IRB # 16294
Phase I Safety and Tolerability of ZEN003694 w/ enzalutamide or abiraterone acetate

IRB # 17864
Phase III Study of Rucaparib versus physician’s choice for patients with mCRPC associated with Homologous Recombination Deficiency

IRB # 18231
Phase I/2a Study of CORT125281 and enzalutamide

IRB # 18231
Phase 1/2a Study of CORT125281 and enzalutamide

IRB # 18231
Phase 1/2a Study of CORT125281 and enzalutamide

IRB # 19002
Lu-PSMA radionuclide in PSMA-Positive mCRPC

IRB # 15921
INTERVAL: Intense exercise for survival among men with mCRPC

IRB # 15944
Falls in Elderly Men Taking Enzalutamide

IRB # 17717
Degarelix, apalutamide, abiraterone acetate in biochemically relapsed prostate cancer

New Trial Coming Soon

New Trial Coming Soon

New Trial Coming Soon

New Trial Coming Soon

New Trial Coming Soon

New Trial Coming Soon

New Trial Coming Soon

New Trial Coming Soon

IRB # 16837
International Registry for Men with Advanced Prostate Cancer

Key

Open for Enrollment

In Development

Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

6/26/2019